Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,320 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PET (Positron Emission Tomography) Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome

NCT03370614
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
IBS Group, Healthy Control Group
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Villanova, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Phase 2 Interventional Results available

Tau Imaging of Chronic Traumatic Encephalopathy

NCT02191267
View directory record Official record
Conditions
Chronic Traumatic Encephalopathy
Interventions
[F18]-T807, [F18]-Florbetapir, MRI/MRS, Genetic Analysis for Genetic Risk Score for Tau.
Radiation · Device · Genetic
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 22, 2026, 11:20 AM EDT
Recruiting Phase 3 Interventional

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

NCT06625034
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy Treatment Planning and Simulation
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

NCT03440112
View directory record Official record
Conditions
Parkinson Disease
Interventions
Clarithromycin (Not used as of 4/2020), Placebo (Not used as of 4/2020), Transdermal flumazenil (Added 4/2020), Placebo (Added 4/2020)
Drug
Lead sponsor
Nicolaas Bohnen, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Not applicable Interventional

Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System

NCT01008930
View directory record Official record
Conditions
Solid Tumors, Cancer
Interventions
HR PEM Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 22, 2026, 11:20 AM EDT
Recruiting Phase 2 Interventional

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

NCT04665739
View directory record Official record
Conditions
Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 11:20 AM EDT
Not yet recruiting Early Phase 1 Interventional

[Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers

NCT07026981
View directory record Official record
Conditions
Head and Neck Cancer, Pancreatic Cancer, Cancer Pancreas
Interventions
[Ga-68]MTP220 PET/CT Scan
Drug
Lead sponsor
Qiubai Li
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 22, 2026, 11:20 AM EDT
Active, not recruiting No phase listed Observational

Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT

NCT03846167
View directory record Official record
Conditions
Breast Cancer
Interventions
Imaging Drug FluorThanatrace (FTT)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 22, 2026, 11:20 AM EDT
Withdrawn Phase 3 Interventional

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

NCT04139395
View directory record Official record
Conditions
Fever of Unknown Origin
Interventions
68Ga-Citrate PET/MRI, 67Ga-Citrate SPECT, Positron Emission Tomography, Magnetic Resonance Imaging, SPECT
Drug · Device
Lead sponsor
Carina Mari Aparici
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 22, 2026, 11:20 AM EDT
Recruiting Phase 2 Interventional

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

NCT06765317
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Interventions
Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin, Obinutuzumab:
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Early Phase 1 Interventional

Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

NCT04899180
View directory record Official record
Conditions
Aortic Stenosis, Transthyretin Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
Interventions
99mTc-PYP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
75 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 22, 2026, 11:20 AM EDT
Active, not recruiting Phase 2 Interventional Results available

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

NCT04895735
View directory record Official record
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
Interventions
Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 11:20 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma

NCT05322135
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
18F-FSPG, 11C-Glutamine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 22, 2026, 11:20 AM EDT
Not listed Phase 3 Interventional

Heartflow (AFFECTS)

NCT02973126
View directory record Official record
Conditions
Cardiovascular Abnormalities
Interventions
FFRct and SPECT
Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Phase 2 Interventional

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

NCT05133440
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium dichloride, PET Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 11:20 AM EDT
Completed No phase listed Observational

Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial

NCT07255482
View directory record Official record
Conditions
Thyroid Nodule (Benign), Thyroid Nodule (Diagnosis), Thyroid Cancer
Interventions
Thyroid Ultrasound
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 11:20 AM EDT
Not listed Phase 2 Interventional

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

NCT01260480
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
Interventions
[18F]-ML-10 in conjunction with PET imaging
Other
Lead sponsor
Aposense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Teaneck, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2010 · Synced Oct 22, 2026, 11:20 AM EDT
Recruiting Phase 2 Interventional

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

NCT06495125
View directory record Official record
Conditions
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Endotoxin-induced iNOS Activation

NCT01407796
View directory record Official record
Conditions
Pneumonia
Interventions
Endotoxin (E. coli O:113, Reference Endotoxin), [18F](+/-)NOS
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444

NCT05009199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[18F]MNI-444
Drug
Lead sponsor
Invicro
Other
Eligibility
30 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Phase 1 Interventional Results available

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

NCT02333487
View directory record Official record
Conditions
Schizophrenia
Interventions
Lu AF35700
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 22, 2026, 11:20 AM EDT
Completed Not applicable Interventional

FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer

NCT00282906
View directory record Official record
Conditions
Prostate Cancer
Interventions
hybrid PET-CT imaging system
Device
Lead sponsor
University of Southern California
Other
Eligibility
21 Years and older · Male only
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 22, 2026, 11:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Scan to Study Brain Control of Human Movement

NCT00001324
View directory record Official record
Conditions
Ataxia, Cerebrovascular Accident, Healthy, Movement Disorder, Tremor
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 22, 2026, 11:20 AM EDT